The Canadian experience with long-term deflazacort treatment in Duchenne muscular dystrophy
about
Current and emerging treatment strategies for Duchenne muscular dystrophyDiscovery of serum protein biomarkers in the mdx mouse model and cross-species comparison to Duchenne muscular dystrophy patients.Genetic modifiers of ambulation in the Cooperative International Neuromuscular Research Group Duchenne Natural History StudyLarge-scale serum protein biomarker discovery in Duchenne muscular dystrophyImproving clinical trial design for Duchenne muscular dystrophy.Discovery of Metabolic Biomarkers for Duchenne Muscular Dystrophy within a Natural History Study.Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study.Corticosteroid Treatment and Growth Patterns in Ambulatory Males with Duchenne Muscular Dystrophy.Identification of serum protein biomarkers for utrophin based DMD therapy.Corticosteroid Treatment Impact on Spinal Deformity in Duchenne Muscular Dystrophy.MicroRNA and mRNA Expression Changes in Steroid Naïve and Steroid Treated DMD Patients.Fat embolism after fractures in Duchenne muscular dystrophy: an underdiagnosed complication? A systematic reviewDiagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management.SU9516 Increases α7β1 Integrin and Ameliorates Disease Progression in the mdx Mouse Model of Duchenne Muscular Dystrophy.
P2860
Q26741535-3562BC4B-9CC4-4630-B5AD-758B9F441F39Q34555477-63B19256-917B-4AAF-A394-2554E671DBD9Q35495274-4E2A66C4-E72C-4DD8-86EA-0EF646A8B798Q35740280-4E746F23-DEC2-4F0B-A359-E6979DF1AA5FQ35755174-9B53BBEB-7F68-4902-A0AD-9996BFB92873Q35991086-5C75FE67-CB3F-4C97-B270-EF102D3368ADQ36155677-CC87F5B4-4AE8-4B0E-8A78-1BC97D297D8CQ37400938-4A03075A-340E-44DC-8F77-7920CA268959Q37676311-BD748F51-F80E-44AB-ACC4-DBBA15DF87D0Q38887550-2090D650-80B8-4FD6-8FF9-7250D56FB600Q39178174-E19BA5A8-86C3-4C49-A4B4-447C1F318F4AQ42687917-C2017A76-86F9-4507-8389-A5494C7DD479Q50207382-E95FFE41-7A05-4BDC-920F-1DFCC8227085Q51065898-1386FAC4-1F68-40F0-91FE-BE0E275CCB4C
P2860
The Canadian experience with long-term deflazacort treatment in Duchenne muscular dystrophy
description
2012 nî lūn-bûn
@nan
2012 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
The Canadian experience with l ...... in Duchenne muscular dystrophy
@ast
The Canadian experience with l ...... in Duchenne muscular dystrophy
@en
The Canadian experience with l ...... in Duchenne muscular dystrophy
@nl
type
label
The Canadian experience with l ...... in Duchenne muscular dystrophy
@ast
The Canadian experience with l ...... in Duchenne muscular dystrophy
@en
The Canadian experience with l ...... in Duchenne muscular dystrophy
@nl
prefLabel
The Canadian experience with l ...... in Duchenne muscular dystrophy
@ast
The Canadian experience with l ...... in Duchenne muscular dystrophy
@en
The Canadian experience with l ...... in Duchenne muscular dystrophy
@nl
P2093
P2860
P1433
P1476
The Canadian experience with l ...... in Duchenne muscular dystrophy
@en
P2093
Amanda L Mayo
Benjamin A Alman
Laura C McAdam
W Douglas Biggar
P2860
P577
2012-05-01T00:00:00Z